Cargando…
Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study
Tumour angiogenesis plays a key role in tumour growth, formation of metastasis, detection and treatment of malignant tumours. Recent investigations provided increasing evidence that quantitative analysis of tumour angiogenesis is an indispensable prerequisite for developing novel treatment strategie...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746600/ https://www.ncbi.nlm.nih.gov/pubmed/12085213 http://dx.doi.org/10.1038/sj.bjc.6600318 |
_version_ | 1782172055264821248 |
---|---|
author | Pahernik, S Harris, A G Schmitt-Sody, M Krasnici, S Goetz, A E Dellian, M Messmer, K |
author_facet | Pahernik, S Harris, A G Schmitt-Sody, M Krasnici, S Goetz, A E Dellian, M Messmer, K |
author_sort | Pahernik, S |
collection | PubMed |
description | Tumour angiogenesis plays a key role in tumour growth, formation of metastasis, detection and treatment of malignant tumours. Recent investigations provided increasing evidence that quantitative analysis of tumour angiogenesis is an indispensable prerequisite for developing novel treatment strategies such as anti-angiogenic and antivascular treatment options. Therefore, it was our aim to establish and validate a new and versatile imaging technique, that is orthogonal polarisation spectral™ imaging, allowing for non-invasive quantitative imaging of tumour angiogenesis in vivo. Experiments were performed in amelanotic melanoma A-MEL 3 implanted in a transparent dorsal skinfold chamber of the hamster. Starting at day 0 after tumour cell implantation, animals were treated daily with the anti-angiogenic compound SU5416 (25 mg kg bw(−1)) or vehicle (control) only. Functional vessel density, diameter of microvessels and red blood cell velocity were visualised by both orthogonal polarisation spectral™ imaging and fluorescence microscopy and analysed using a digital image system. The morphological and functional properties of the tumour microvasculature could be clearly identified by orthogonal polarisation spectral™ imaging. Data for functional vessel density correlated excellently with data obtained by fluroescence microscopy (y=0.99x+0.48, r(2)=0.97, R(S)=0.98, precision: 8.22 cm(−1) and bias: −0.32 cm(−1)). Correlation parameters for diameter of microvessels and red blood cell velocity were similar (r(2)=0.97, R(S)=0.99 and r(2)=0.93, R(S)=0.94 for diameter of microvessels and red blood cell velocity, respectively). Treatment with SU5416 reduced tumour angiogenesis. At day 3 and 6 after tumour cell implantation, respectively, functional vessel density was 4.8±2.1 and 87.2±10.2 cm(−1) compared to values of control animals of 66.6±10.1 and 147.4±13.2 cm(−1), respectively. In addition to the inhibition of tumour angiogenesis, tumour growth and the development of metastasis was strongly reduced in SU5416 treated animals. This new approach enables non-invasive, repeated and quantitative assessment of tumour vascular network and the effects of antiangiogenic treatment on tumour vasculature in vivo. Thus, quantification of tumour angiogenesis can be used to more accurately classify and monitor tumour biologic characteristics, and to explore aggressiveness of tumours. British Journal of Cancer (2002) 86, 1622–1627. DOI: 10.1038/sj/bjc/6600318 www.bjcancer.com © 2002 Cancer Research UK |
format | Text |
id | pubmed-2746600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27466002009-09-18 Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study Pahernik, S Harris, A G Schmitt-Sody, M Krasnici, S Goetz, A E Dellian, M Messmer, K Br J Cancer Experimental Therapeutics Tumour angiogenesis plays a key role in tumour growth, formation of metastasis, detection and treatment of malignant tumours. Recent investigations provided increasing evidence that quantitative analysis of tumour angiogenesis is an indispensable prerequisite for developing novel treatment strategies such as anti-angiogenic and antivascular treatment options. Therefore, it was our aim to establish and validate a new and versatile imaging technique, that is orthogonal polarisation spectral™ imaging, allowing for non-invasive quantitative imaging of tumour angiogenesis in vivo. Experiments were performed in amelanotic melanoma A-MEL 3 implanted in a transparent dorsal skinfold chamber of the hamster. Starting at day 0 after tumour cell implantation, animals were treated daily with the anti-angiogenic compound SU5416 (25 mg kg bw(−1)) or vehicle (control) only. Functional vessel density, diameter of microvessels and red blood cell velocity were visualised by both orthogonal polarisation spectral™ imaging and fluorescence microscopy and analysed using a digital image system. The morphological and functional properties of the tumour microvasculature could be clearly identified by orthogonal polarisation spectral™ imaging. Data for functional vessel density correlated excellently with data obtained by fluroescence microscopy (y=0.99x+0.48, r(2)=0.97, R(S)=0.98, precision: 8.22 cm(−1) and bias: −0.32 cm(−1)). Correlation parameters for diameter of microvessels and red blood cell velocity were similar (r(2)=0.97, R(S)=0.99 and r(2)=0.93, R(S)=0.94 for diameter of microvessels and red blood cell velocity, respectively). Treatment with SU5416 reduced tumour angiogenesis. At day 3 and 6 after tumour cell implantation, respectively, functional vessel density was 4.8±2.1 and 87.2±10.2 cm(−1) compared to values of control animals of 66.6±10.1 and 147.4±13.2 cm(−1), respectively. In addition to the inhibition of tumour angiogenesis, tumour growth and the development of metastasis was strongly reduced in SU5416 treated animals. This new approach enables non-invasive, repeated and quantitative assessment of tumour vascular network and the effects of antiangiogenic treatment on tumour vasculature in vivo. Thus, quantification of tumour angiogenesis can be used to more accurately classify and monitor tumour biologic characteristics, and to explore aggressiveness of tumours. British Journal of Cancer (2002) 86, 1622–1627. DOI: 10.1038/sj/bjc/6600318 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-20 2002-05-03 /pmc/articles/PMC2746600/ /pubmed/12085213 http://dx.doi.org/10.1038/sj.bjc.6600318 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Experimental Therapeutics Pahernik, S Harris, A G Schmitt-Sody, M Krasnici, S Goetz, A E Dellian, M Messmer, K Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
title | Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
title_full | Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
title_fullStr | Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
title_full_unstemmed | Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
title_short | Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
title_sort | orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746600/ https://www.ncbi.nlm.nih.gov/pubmed/12085213 http://dx.doi.org/10.1038/sj.bjc.6600318 |
work_keys_str_mv | AT paherniks orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy AT harrisag orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy AT schmittsodym orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy AT krasnicis orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy AT goetzae orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy AT dellianm orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy AT messmerk orthogonalpolarisationspectralimagingasanewtoolfortheassessmentofantivasculartumourtreatmentinvivoavalidationstudy |